The Drug-Induced Respiratory Disease Website
De novo chronic, progressive or acute LV dysfunction/failure. May result from myocarditis or eosinophilic myocarditis. May cause congestive heart failure and/or pulmonary edema (see under II). Hypertension may be present. Symptoms range from worsening of preexisting LVF to acute cardiogenic pulmonary edema, shock or cardiopulmonary arrest. See also pulmonary edema under IId, and XIId, XIIf. Review at PMID 10193711, 16808550, 18083403, 21930637
Publications
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma.
Cardio-oncology (London, England) 2018;4;2 — 2018 — 2
Rosenthal A, Luthi J, Belohlavek M, Kortüm KM, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart AK
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Blood cancer journal 2016 Jan 15;6;e384 — 2016 Jan 15 — e384
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
BMC cancer 2014 Dec 04;14;915 — 2014 Dec 04 — 915